贝那普利与美托洛尔联用治疗慢性充血性心力衰竭的临床观察  

Clinical observation of benazepril plus metoprolol in the treatment of chronic congestive heart failure

作　　者：林劲[1] 翟任群[1] 吴明[1] 

机构地区：[1]海南省人民医院心内科,海南省海口570311

出　　处：《中国基层医药》2006年第12期1953-1955,共3页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的观察贝那普利和美托洛尔(倍他乐克)联合应用治疗慢性充血性心力衰竭(CHF)的临床疗效。方法采用贝那普利和美托洛尔联合治疗CHF患者42例,并与单独应用贝那普利治疗的40例患者进行比较,观察用药前后收缩压(SBP)、舒张压(DBP)、HR、左室收缩末内径(LVESd)、左室舒张末内径(LVEDd)及左室射血分数(LVEF)的变化。结果治疗组与对照组的总有效率分别为95.2%和80.0%(P<0.05),治疗组SBP、DBP、HR、LVESd、LVEDd均明显下降(P<0.05),LVEF增加明显(P<0.05)。结论贝那普利联合美托洛尔治疗慢性充血性心力衰竭安全有效,可明显提高CHF的疗效。Objective To observe the clinical therapeutic effect of benazepril plus betaloc in the treatment of chronic congestive heart failure（CHF）. Methods 42 cases with CHF were treated with benazepril plus betaloc, the therapeutic effect was compared with 40 cases treated with benazepril alone. Before and after treatment, to observe the changes of systolic pressure（SBP）, diastolic pressure（DBP）, heart rate（HR）, left vantricular end systolic diameter （LVESd） ,left ventricular end diastolic diameter（LVEDd） and left ventricular ejection fraction（LVEF） were observed. Results The general effective rate in treatment group and control group was 95.2 % and 80.0 %, respectively. The SBP ,DBP, HR ,LVESd and LVEDd in treatment group decreased obviously（ P 〈 0.05 ）, but the LVEF increased obviously（P〈 0.05）. Conclusion Benazepril plus betaloc in the treatment of CHF is safe and effective, and it can improve the therapeutic effect of CHF.

关 键 词：心力衰竭 充血性 贝那普利 美托洛尔 

分 类 号：R541.6[医药卫生—心血管疾病]